Mogrify

Mogrify

Mogrify is developing tailored cellular conversions that power future cell therapies.

Mogrify has developed a proprietary direct cellular conversion technology, which makes it possible to transform (transmogrify) any mature human cell type into any other without going through a pluripotent stem cell- or progenitor cell-state.

In a collaboration with Sangamo, Mogrif’s cell conversion technology will be applied to generate regulatory T cells (Tregs) from pluripotent stem cells and embryonic stem cells. Sangamo aims to apply its ZFP gene engineering technology to Tregs as allogeneic cell therapies to treat inflammatory and autoimmune diseases.

Timeline

October 14, 2019
Mogrify raises $3.7M in seed capital, appoints Dr. Darrin M. Disley, OBE as CEO, launches the Mogrify V2 and Epimogrify V1 platforms, and is raising an additional $16 million USD in the initial close of its Series A funding.
October 14, 2019
Mogrify raises a $16,000,000 series A round from Ahren Innovation Capital.
October 2019
Mogrify raises a $16,000,000 series A round from Ahren Innovation Capital, Parkwalk Advisors, University of Bristol Enterprise Fund and 24Haymarket.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Mogrify Ltd funding round, October 2019
16,000,000
October 2019
2 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Alex Keown
November 6, 2020
BioSpace
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.